Oncoinvent ASA: Resolution to increase the share capital in connection with settlement of underwriting fee
Oncoinvent ASA resolved to increase its share capital by NOK 15,599,998.50 to issue shares for settling underwriting fees related to a recent rights issue.Summary
Oncoinvent ASA announced a resolution to increase its share capital by NOK 15,599,998.50 through the issuance of 31,199,997 new shares. This increase is to settle the underwriting fee for a previously announced rights issue of 260,000,000 new shares, aiming to raise NOK 130 million. The shares will be delivered to underwriters at a subscription price of NOK 0.50, consistent with the rights issue price. Registration with the Norwegian Register of Business Enterprises is expected around December 9, 2025, with delivery to underwriters around December 10, 2025.
Oncoinvent ASA is a clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer, with Radspherin® as its lead product candidate. Radspherin® targets micro-metastases in the peritoneum post-surgery using radium-224.
The company is currently conducting clinical trials for Radspherin® in ovarian cancer and has reported encouraging early efficacy data with no significant safety concerns.
(Source：Euronext Markets)